Early Phase 1 N=80 Alcohol, Behavior, and Brain Imaging
Alcohol Drinking · Binge Drinking · Drinking Behavior
Primary: Stop Signal Task (SST) — 255; 215 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Prevention of Alcohol Intolerance
Alcohol Sensitivity
Primary: Mean Area of Skin Erythema (Skin Redness) — 3.968; 1.739 centimeters^2
N/A N=122 PrEP and Alcohol - Enhancing HIV Pre-Exposure Prophylaxis (PrEP)
Hazardous Alcohol Use
Primary: Intervention Feasibility: Intervention Uptake — 122 Participants
Phase 2 N=32 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
Early Phase 1 N=8 Imaging Glutamate Release From Alcohol
Alcohol Drinking
Primary: Alcohol-induced Change in Receptor Availability — -9.1 percentage change of BP_ND
N/A N=94 Pharmacogenetics of Alcohol: Treatment Implications
Alcohol Related Disorders · Alcoholism · Alcohol Abuse
Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28
N/A N=360 Alcohol Metabolism and Disease Risk in Asians
Healthy
Primary: Peak Number of Alcohol Drinks Consumed in a Day — 3.7; 4.2; 3.4; 3.0 drinks — p=.81
N/A N=180 Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Alcoholism
Primary: Number of Drinks Felt Consumed at Baseline — 0; 0; 0; 0 drinks felt consumed
Phase 1 N=33 Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans
Active Ethanol and Active Iomazenil · Active Ethanol and Placebo Iomazenil · Placebo Ethanol and Active Iomazenil
Primary: Biphasic Ethanol Effects Scale (BAES) — 3.767; 3.935; 3.813; 3.194 score on a scale
Phase 1 N=34 Mavoglurant in Alcohol Drinking
Alcohol Drinking
Primary: Abnormal Labs and Adverse Events — 9; 8; 0; 0 Participants
N/A N=73 GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence
Alcoholism
Primary: Visual Analog Scales of Similarity to Alcohol - Baseline — 0; 0; 0; 0 units on a scale
Early Phase 1 N=30 Behavior Brain Responses
Alcohol Drinking · Drinking Behavior · Physiological Effects of Drugs
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Across Sessions…
N/A N=93 Testing Brief Personalized Feedback Integrating Lab-based Alcohol Cue Information
Alcohol Consumption
Primary: Daily Drinking Questionnaire — 10.24; 12.27; 8.79; 9.73 Drinks per week — p=0.83
N/A N=1,053 Evaluations of Alcohol Warning Labels
Oral Cancer · Esophageal Cancer · Larynx Cancer
Primary: Dwell Time — 8.75; 8.47 seconds
Phase 2 N=55 Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
Alcohol Use Disorder
Primary: Change in Stress-reactivity as Assessed by Heart Rate Change During the Cold Pressor Task (CPT) — 5.138; 12.154 beats per minutes (bpm)
Early Phase 1 N=14 Influence of n-Acetylcysteine Maintenance on Alcohol Effects
Alcohol Use Disorder
Primary: Number of Alcohol Drinks Chosen — 3.1; 2.8; 3.8 Number of Alcohol Drinks Chosen
N/A N=16 Effects of Alcoholic Beverages in Pro-inflammatory and Antioxidant Profile After an Oral Fat Diet
Alcohol Consumption
Primary: Change From Baseline in Concentrations of Antioxidant Profile After Red Wine Intake — 22.3; 12.7 percentage of change in TAC — p=0.05
Phase 2 N=14 A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking
Alcoholism
Primary: Alcohol Urge — 22.5; 19.4 units on a scale
N/A N=640 Understanding Alcohol Reward in Social Context
Alcohol Drinking · Alcohol Use Disorder · Alcohol Intoxication
Primary: Self-Reported Emotion — 3.49; 2.98; 0.32; 0.673 score on a scale — p=<0.001
Phase 2 N=22 Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy
Alcohol Drinking
Primary: Number of Drinks Consumed During an Ad-libitum Drinking Period — 1.59; 1.64 drinks
Phase 2 N=50 Medication Development in Alcoholism: Investigating PPAR Agonists
Alcoholism
Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period — 8.94; 10.37; 9.83; 11.03 units on a…
Phase 2 N=70 Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
Alcoholism
Primary: Startle Potentiation During Stress Reactivity Task. — 45.7; 40.1; 33.2; 25.2 startle potentiation (μV)
Phase 1 N=5 Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
Alcohol Drinking
Primary: Safety/Tolerability of Study Medication. — 0 participants
N/A N=1,123 Impacts of Alcohol Warning Labels: An Online Experiment
Alcohol Drinking
Primary: Perceived Message Effectiveness — 2.66; 2.54; 2.52; 2.50 score on a scale — p=<0.001
N/A N=11 Effect of Theta Burst Stimulation on Alcohol Cue Reactivity
Alcohol Drinking · Alcohol Use Disorder · Trauma Injury
Primary: Behavioral Outcomes: Change in the k-Value, a Measure of Delay Discounting of Alcohol — -0.12; -7.42 Change in k-value
Phase 4 N=122 Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department
Nausea
Primary: Nausea 100 mm Visual Analogue Scale (VAS) — 23; 19; 42 units on a scale
Phase 2 N=22 Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
Alcoholism
Primary: Biphasic Alcohol Effects Scale (BAES): Stimulant Subscale — 13.756; 14.053; 13.026 score on a scale — p=0.867
N/A N=45 Effects of Ghrelin on Alcohol Cue Reactivity and Craving
Alcoholism
Primary: Alcohol Visual Analogue Scale (A-VAS) — 1.95; 2.66; 4.29 units on a scale
N/A N=24 Effects of Acetate and Alcohol on Brain Function
Cerebral Blood Flow · Brain Function
Primary: Change in Cerebral Blood Flow as Measured With Arterial Spin Labeling — 31.7; 26.9; 30.0; 25.0 cc/100 mg/min
Phase 2 N=71 Functional Neuroimaging of Alcoholism Vulnerability (PIT)
Healthy
Primary: Change in Blood Oxygenation Level Dependent (BOLD) Activation in the Amygdala During "Win" Monetary Incentive Delay (MID) Task Between Placebo and Study Medication…